Diabetes Mellitus, Type 2
Conditions
Brief summary
This study aims to describe demographics, clinical, treatment and healthcare resource utilization characteristics with a particular focus on those relating to cardiovascular disease in selected treatment intensified patients with type 2 diabetes in the real-world settings in India, Pakistan, and Thailand. The study will be based on data already recorded in participants medical record and no new tests or procedures are required as part of the study. The study will last for about 6 months and it does not affect participants current treatment.
Interventions
OTHERNo treatment given
The study will be based on data already recorded in the medical record
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. Male or female, age above or equal to 18 years at type 2 diabetes mellitus (T2DM) diagnosis 3. Year of birth 1928 or later (age blow 90 years old in 2017) 4. T2DM diagnosis in medical record on or after the date of local GLP-1 RA marketing authorization 5. Medical records documenting prior or ongoing treatment with metformin 6. Medical records documenting treatment with other non-metformin T2DM drugs
Exclusion criteria
1. Previous participation in this study. Participation is defined as having given informed consent in this study. 2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. 3. Patients with any diagnosis of type 1 diabetes mellitus (T1DM)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of patients prescribed cardiovascular disease (CVD) medications | Since the start of medical record | Will be reported as percent of patients |
| BMI (body mass index) | 6 months prior to Baseline (day 0, defined as the date of first prescription for the most recent antidiabetic medication drug class) (retrospective) | BMI will be calculated from height and weight data reported as percent of patients |
| Most recent blood pressure measurement values | 6 months prior to Baseline (day 0, defined as the date of first prescription for the most recent antidiabetic medication drug class) (retrospective) | Reported as mmHg |
| The proportion of patients prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RA) | At Baseline (day 0, defined as the date of first prescription for the most recent antidiabetic medication drug class) | Will be reported as percent of patients |
Countries
India, Pakistan, Thailand
Outcome results
None listed